Social networking key to new healthcare models

by IainBate 18. May 2012 15:02

Pharma Industry News Social Networking is set to play a key role in delivery of new models of healthcare, a new report predicts.

Interactive websites such as Facebook, Twitter and LinkedIn are expected to be utilised by providers of healthcare in Europe to help tackle existing and future challenges.

The report, Cooperation, Communication, Coordination: Three Pillars of Collaborative Teamwork anticipates networking sites to be used to increase awareness in disease management and clinical trial recruitment.

Faced with issues such as cost constraints, ageing populations, a higher incidence of chronic diseases, regulatory pressures and the need for improved quality of care and patient safety, the report says effective teamwork is needed to implement new delivery methods.

Alongside social networking, the report highlights cooperation between different divisions, access to real-time data and mobile technologies as also playing an important part in delivering these new healthcare models.

“Teamwork and collaboration are often used synonymously, but they are not the same,” said Jan Duffy, EMEA Research Director, IDC Health Insights – who conducted the report.

“Effective collaboration may be viewed as either a process which affects the results of teamwork – enhanced patient care and provider satisfaction – or an outcome in and of itself. Whether or not it is an ingredient or a by-product of teamwork, it is certain that the seamless provision of quality patient care today and in the future depends on inter-professional collaboration.”

Roche sponsors diabetes Twitter site

by JoelLane 30. March 2012 14:38

Pf industry news Roche plans to use the Twitter-based Diabetes Nest social network as a means to interact in real time with diabetes patients, carers and health professionals.

The company’s diabetes care business will sponsor the site, run by agency Ignite Health, which collects, sorts and ranks tweets from diabetes experts.

Roche Diabetes Care will also add a widget with content from the Diabetes Nest to the company’s community web page, Accu-Chek Diabetes Link.

The Diabetes Nest sends the week’s top 10 curated tweets to community members via an e-newsletter.

Rob Muller, Associate Marketing Manager for Roche Diabetes Care, said: “We are very proud to support such a great resource that can help people with diabetes stay up to date with their friends on Twitter, or even help them discover more of the diabetes online community there.”

Fabio Gratton, Chief Experience Officer at Ignite Health, explained the site’s rationale: “Social media have transformed how patients and their caregivers share healthcare information and find support. But the sheer volume of content can be overwhelming.

“So we asked ourselves how we could best help the diabetes community find and engage in the most timely, relevant and important conversations. The result is a simple, intuitive, compelling and ultimately self-sustaining diabetes social media community.”

“The Diabetes Nest highlights many of the most influential voices and topics in the diabetes Twittersphere, helping to raise the collective voice of our community,” commented health blogger Kerri Sparling.

“The Diabetes Nest gives a cumulative snapshot into what real life with diabetes is really like.”

Allergan tweet breaches industry code

by JoelLane 27. January 2012 15:21

Pf industry news Careless use of Twitter by an Allergan employee has led to the company being ruled in breach of the ABPI’s Code of Practice.

The employee told a friend working for a patient organisation that Allergan might “do something around stroke rehab” using the company’s Botox product.

The tweet, which was not authorised by Allergan, was read by the followers of the sender and the recipient, including members of the patient organisation.

Because Botox has prescription-only applications in stroke treatment, the tweet was judged to be public advertising of a prescription-only drug.

The employee’s mistake may have been a purely technical one – sending the message as ‘public’ rather than ‘private’ – rather than any misunderstanding of the Code of Practice.

However, the Prescription Medicines Code of Practice Authority (PMCPA) ruled that Allergan had breached clauses 9.1 and 22.1 of the Code.

It commented that the company had been “badly let down by its employee” and further noted: “In the Panel’s view, pharmaceutical company employees needed to be extremely cautious when using social media.”

According to the company’s policy, Allergan’s employees are not allowed to comment on its products or business activity in social media forums.

Allergan has since updated its social media policy and sent its UK employees a copy of the PMCPA’s digital guidance. The company intends to provide its employees with further training on the Code.

Tags: , , , , , , ,

News

Pfizer tops social media chart

by IainBate 22. December 2011 13:28

Pharma Industry News Pfizer has been crowned the leading pharmaceutical company for their presence on Facebook and Twitter, a new study has found.

Cegedim Strategic Data (CSD) found the pharma-giant had the third-most ‘likes’ on Facebook and had more followers on Twitter than industry rivals. Novartis were ranked overall in second with Merck & Co in third position.

Christopher Wooden, Vice President, Promotion Audits for CSD, says the audit highlights how the industry is improving its social media footprint.

The study was conducted worldwide and focused on the top 100 pharmaceutical companies in terms of traditional sales force and marketing channel spending. CSD then identified the top 30 pharma companies for their presence and healthcare-focused activities on Twitter and Facebook.

Behind Pfizer, Novartis was ranked seventeenth for ‘likes’ on Facebook and overall fifth on Twitter for its number of followers. Merck – which came first for the number of pages on Facebook – ranked tenth for the number of ‘likes’ it has received, third for the number of ‘tweets’ it has made on Twitter and fifteenth for its followers.

CSD found that J&J is second for the number of ‘likes’ on Facebook with Roche occupying the same position for its number of followers on Twitter.

“The CSD social media audit shows clearly that most major life science companies are establishing a presence in social media – but coverage, methods and sophistication do vary significantly,” said Christopher Wooden.

“In broad terms we see an attempt by companies to reach out and create a positive, on-going message about their contribution to better health. The ability to target that message and encourage constructive dialogue through social media will bring value to companies developing this new channel.”

To infinity and beyond

by emma 3. November 2011 15:22

Pharma Field - To infinity and beyond

Despite huge investments into CRM systems some pharma companies still struggle to get all of their staff to embrace and fully interact with them. Pf’s Iain Bate explores why, and what the future holds for technology in the industry.

There’s no doubt that technological developments have changed the way we live and work from year to year – maybe even from month to month in the 21st Century. But has the world of healthcare been travelling in the slow lane of the intergalactic highway?

The potential that technology offers to pharma, and the general world of healthcare, is enormous. But is the pharmaceutical industry, and its staff in particular, using it to maximise the returns of billion-dollar investments?

It would seem that technology is the ‘buzz word’ on the lips of a few of healthcare’s major players at present. The DH recently invited people to nominate their favourite health-related mobile phone ‘app’ – be it for keeping fit, to locate a hospital or chemist, or helping to manage an illness. Creative minds were also asked to design their own health app with a panel of DH judges deciding on their favourite from the most popular entries.

Health Secretary Andrew Lansley says it’s the Government’s intention to give people better access to information using modern technology and the exercise is a “unique opportunity for the NHS and those who develop apps to not only showcase their work, but to bring to life new ideas and realise true innovation in healthcare”.

As part of the DH’s technology revolution, patients may also soon be offered online consultations with their GPs using programmes such as Skype. Clearly the Government is embracing the convenience technology offers to patients, but are other sectors in healthcare as interested? It would seem there is still some way to go.

 

In two minds

Pf ’s 2010/11 annual Company Perception, Motivation and Satisfaction Survey suggests that not all respondents are completely convinced by the power of technology in the workplace. Although the Survey – which relates to 2010 and the early part of this year – found that nearly 90% of respondents have access to a CRM system, only 43% find time to use it in the field and more than a fifth of people fail to accurately record post-call reports with important clients.

Questions have to be asked as to why, despite multimillion pound investment and training by pharma companies, there remains a percentage of staff that still ignore the power and potential of the technology at their finger tips.

Results from the Survey reveal there’s no difference in uptake by key account managers, primary and secondary care representatives, those in primary care roles only, firstline sales managers and secondline sales managers and the use of CRM technology between differing age groups – although surprisingly 10% of respondents in these positions with less than two years of experience said they did not have a CRM system, compared to just 5% more experienced colleagues.

The launch of the iPad in March 2010 promised to revolutionise the way sales representatives, and those in similar roles, use CRM systems in the field. However, nearly three-quarters (70%) of respondents from the Survey are still presently sent out with laptops containing their customer-relationship systems.

When quizzed on what they’d change about the hardware which houses their system, the majority of respondents said that their CRM was too awkward to carry, with poor running systems an issue and that batteries ran out too quickly. Apple claims its second-generation iPad now enjoys ten hours of use away from a plug socket in the field.

Yet the switch to the latest convenient tablet devices may not necessarily be about high levels of investment, it may be down to maximising value for money as Paul Shawah, Vice President, Multi Channel Strategy, Veeva Systems explains. “I would say the life cycle of devices within the industry is generally about three years, sometimes a little bit longer,” he said. “When a company invests in new technology they typically depreciate that over that period, so they don’t want to replace it in the field for that time to maximise their investment.

“However, with the introduction of game changing technology like the iPad, this has changed. We see a number of our pharmaceutical customers are justifying the business case to move to the iPad even before their tablets are fully depreciated. This speaks to the business benefit that pharma expects to achieve from the iPad and the related applications only available on that device.”

Pf Survey demographic and key CRM results

A convenient shield

Despite technology eliminating mundane process in the workplace and offering the potential to assist employees and improve their efficiency at work, it has historically been used as a shield to mask poor performance and abused as a means to waste company time – a recent online survey by AOL found that nearly half of Americans (44.7%) rank surfing the web as their primary activity during the two hours they ‘waste’ each day at work.

But it would seem that a high number of respondents do value the opportunities CRM offers. Almost two-thirds (64%) said they always enter correctly the amount of customer sales they make into their CRM. But 21% admitted they fail to always report face-to-face meetings with clients. More surprisingly, over a fifth of participants said they do not always record the number of products they had sold to clients.

The lack of honest accuracy is surprising considering the amount of time spent using CRM systems each day. A third said they spend between one and two hours a day on their system with a fifth spending three hours or more on their CRM. During their time using the management system, more than half (55%) said that call reporting was the most useful feature.

Although respondents were less impressed with the KAM abilities of their software with only 19% believing it to be the most useful facility. When questioned about what they would change given the chance, 45% said they wanted an improved database, over a quarter (28%) called for their system to be overall more useful, and 18% said they would prefer their CRM to be easier to use.

 

The next level

But what of the future of CRM systems? Will they be easier to use and have improved customer databases? David Round, General Manager, UK, Cegedim Relationship Management, says the regular interaction we now have with technology means we’ve all come to expect the latest developments.

“End users are significantly more ‘technology-savvy’ than their counterparts of even five years ago,” he explained. “If anything, the challenge for companies is to ensure that they provide their end users with the types of technology that they use as consumers. It’s also important to focus on the usability of your software to ensure maximum use. Technology companies – and pharma – must work together to develop a better understanding of the interaction, to ensure it meets users’ needs in the field.”

One main reason that users have become more ‘savvy’ is down to the use and interaction with social media. Whether at home or at work, websites such as Twitter, Facebook, LinkedIn and most recently Google+ have driven an increased use of various forms of technology – especially on devices such as smartphones or tablet devices which reps are calling for in the field.

Pharma companies, both in the US and UK, have flirted with the idea of fully embracing the power social media harnesses, but at present are restricted by the PMCPA’s Code of Practice and by the FDA – who has again delayed the publication of its guidance.

The FDA says it is “difficult to provide a timeframe... due to the extensive work and review process, or ‘Good Guidance Practices’, which ensures that FDA’s stakeholders are provided well vetted guidances articulating FDA’s current thinking on a topic”.

Although the FDA may be unsure on how to direct healthcare companies, David Round believes the introduction, both professionally and personally, of social media has had an impact on staff and their expectations.

“For the modern professional person, much of their everyday life is conducted online – for example on shopping, utilities, insurance or booking a holiday – and many users then want the same level of capability from the tools they use in their job,” he added.

Dan Goldsmith, General Manager, Veeva Europe, agrees there has been a significant shift in the way we operate and interact due to our experiences online through tagged posts or hash-tagged searches. But although the 800 million users on Facebook – more than half which ‘log-on’ every day – and 175 million people on Twitter have no problem saying hello to friends, pharma finds it more difficult reaching out to people.

“Social media create a new avenue for healthcare dialogue and will only continue to pervade our lives,” said Dan. “Consequently, I believe that pharma faces two challenges. The first is to decide how to participate in the online dialogue with stakeholders and then to create those interactions through the channels we’re all familiar with, such as Facebook and Twitter.

“The second is to figure out how to leverage the model of social dialogue internally to support stronger collaboration and more focused communication among employees. Already, we see some companies taking advantage of the latest social business tools to connect employees with one another and to access and share information in real time.”

Clearly CRM solution providers understand the potential modern technology and social media platforms offer to companies. Whether pharma and its workforce get fully up to speed on the intergalactic highway sooner or later remains to be seen.

Top-five CRM benefits

Campaigners arrange Health Bill protests

by emma 2. September 2011 12:06

Pf NHS News

Protests are being planned ahead of the Health and Social Care Bill’s passage through Parliament next week.

UNISON and the BMA are planning to show their opposition to the controversial reforms to coincide with report stage and third reading of the Bill on the 6th and 7th September.

Local events nationwide are planned to coincide with Bill entering the House of Commons with NHS staff and patients set to gather for a candlelit vigil outside Parliament. The BMA is also urging campaigners to take part in online action to email their MP signalling their opposition, and to use Twitter and Facebook to voice their concerns.

BMA Council Chairman, Dr Hamish Meldrum, has also written to all MPs saying the reforms still present an “unacceptably high risk to the NHS” warning them it threatens its ability to operate “effectively and equitably, now and in the future”.

Despite the amendments following recommendations from the NHS Future Forum, the Association still believes the Bill should be withdrawn or be subject to further substantial changes.

In his letter, Dr Meldrum continues to warn of the “inappropriate and misguided reliance on ‘market forces’ to shape services” with the Bill creating “a more central role for choice without a full consideration of the consequences” and the “potential to destabilise local health economies”.

There are several specific areas of concern the BMA has on the Bill including:

  • The limit Foundation Trusts (FTs) can generate from private patients
  • The proposed ‘Quality Premium’ for commissioners
  • Forcing all NHS Trusts to become FTs
  • That the Bill reflects an intention that any increase in patients’ choice of providers should not be given a higher priority than tackling health inequalities and promoting integrated care
  • Ensuring there is a robust and transparent process which has the full confidence of the profession when it comes to how ‘failing’ FTs are dealt with
  • The lack of satisfactory assurance that the Secretary of State will have ultimate responsibility for the provision of a comprehensive health service whilst also allowing other bodies, like the new NHS Board and Clinical Commissioning Groups, day-to-day operational independence.

In a response to the concerns over the responsibility of the Secretary of State, the DH says “the Secretary of State will continue to be responsible - as now - for promoting a comprehensive health service. The NHS will always be available to all, free at the point of use and based on need and not on the ability to pay. To say otherwise is absolute nonsense”.

Bayer admonished for promotional ‘tweets’

by diana 5. July 2011 16:28

Twitter Bayer Healthcare has been ruled in breach of the ABPI Code of Practice for assertions made on Twitter that appeared to be promoting medicines to the public.

This is the first time that the PMCPA has investigated a pharmaceutical company for conduct via social media accounts.

The Authority was made aware of the possible breaches by an unnamed healthcare journalist, who drew attention to one of InPharm’s Digital Pharma Blog series that discussed Bayer’s ‘tweets’ in relation to the PMCPA’s recently released Digital Communication Guidance.

The tweets directed readers to pre-approved press releases about the launches Bayer’s drugs Levitra and Sativex. The tweets themselves, however, had not been approved for broadcast.

It was ruled that several breaches of the Code had taken place, essentially due to medicines being promoted to the public, uncertified material being broadcast to the public and high standards not being maintained.

When asked to respond, Bayer admitted that in light of the new Digital Communications Guidance, the tweets were in breach of Clauses 22.1 and 22.2 of the Code as possible advertisements to the public, and apologised.

The company acknowledged the challenge of utilising social media in a compliant way and stated that the complaint had “greatly assisted” it in establishing what use could be made of social media.

However, due to Bayer’s failure to meet the high standards required and publicising of uncertified material, breaches of Clauses 2 and 9.1 were also ruled.

Tags: , , , , ,

News

TextBox

Tag cloud

Calendar

<<  June 2013  >>
MoTuWeThFrSaSu
272829303112
3456789
10111213141516
17181920212223
24252627282930
1234567

View posts in large calendar